Uncover key drivers, emerging technologies, and competitive movements shaping the continuous bio-manufacturing skid market from 2026–2035 with trusted insights from The Business Research Company
What level of CAGR-driven expansion is anticipated in the Continuous Bio-Manufacturing Skid Market between 2026 and 2030?
The continuous bio-manufacturing skid market has experienced significant growth in its size over recent years. Its value is forecast to increase from $1.99 billion in 2025 to $2.26 billion in 2026, achieving a compound annual growth rate (CAGR) of 13.6%. This historical growth can be linked to several factors, including an increase in biologics production volumes, an early move from batch to continuous processing, the growing adoption of modular manufacturing concepts, the expansion of vaccine and enzyme production facilities, and an escalating demand for adaptable manufacturing setups.
The continuous bio-manufacturing skid market is poised for substantial expansion over the next few years, with its size projected to reach $3.73 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 13.3%. This anticipated growth is influenced by the increasing implementation of fully continuous biologics production, elevated investments in advanced bioprocess automation, a rising need for rapid scale-up capacities, the expansion of cell and gene therapy manufacturing, and a greater emphasis on cost-effective biologics production. Prominent trends throughout this period include the wider adoption of continuous and integrated bioprocessing skids, an escalating demand for modular and plug-and-play manufacturing systems, the growing utilization of real-time process monitoring and control, the broadening of single-use continuous biomanufacturing platforms, and an enhanced focus on process efficiency and throughput.
Access Your Free Sample Report for In-Depth Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=28999&type=smp
What Drivers Are Affecting Demand-Supply Dynamics In The Continuous Bio-Manufacturing Skid Market?
The anticipated expansion of the continuous bio-manufacturing skid market is driven by the growing need for biopharmaceuticals. Biopharmaceuticals are defined as medical products originating from biological sources like proteins, nucleic acids, or living cells, utilized for disease treatment, prevention, or diagnosis. This heightened demand for biopharmaceuticals largely stems from the increasing occurrence of chronic and genetic conditions that necessitate sophisticated biologic treatments for proper management. Continuous bio-manufacturing skid technology boosts biopharmaceutical output by facilitating streamlined, automated, and scalable processes, thereby improving efficiency, consistency, and the speed of creating intricate therapies. As an illustration, data from Cardinal Health Inc., a US healthcare firm, revealed that by January 2023, the U.S. possessed 40 FDA-approved biosimilar products, with 25 commercially available. In contrast, as of January 2022, there were 33 FDA-approved biosimilars, of which 21 had entered the market. Consequently, the expanding requirement for biopharmaceuticals is propelling the growth of the continuous bio-manufacturing skid market.
How Is The Continuous Bio-Manufacturing Skid Market Organized Into Various Segments?
The continuous bio-manufacturing skid market covered in this report is segmented –
1) By Product Type: Single-Use Skids, Multi-Use Skids, Modular Skids
2) By Process: Upstream, Downstream, Integrated
3) By Application: Biopharmaceutical Production, Vaccine Manufacturing, Enzyme Production, Cell And Gene Therapy, Other Applications
4) By End-User: Pharmaceutical Companies, Biotechnology Companies, Contract Manufacturing Organizations, Research Institutes, Other End-Users
Subsegments:
1) By Single-Use Skids: Perfusion Bioreactor Skid, Tangential Flow Filtration Skid, Chromatography Skid, Buffer Preparation Skid
2) By Multi-Use Skids: Fed-Batch Bioreactor Skid, Downstream Purification Skid, Ultrafiltration Skid, Viral Inactivation Skid
3) By Modular Skid: Plug And Play Bioreactor Skid, Integrated Downstream Skid, Automated Sampling Skid, Real-Time Monitoring Skid
Which Market Trends Are Opening Growth Opportunities In The Continuous Bio-Manufacturing Skid Market?
Leading firms within the continuous bio-manufacturing skid sector are concentrating on creating innovative solutions, including next-generation platforms for biologics manufacturing, aimed at boosting efficiency, scalability, and the caliber of their products. These advanced systems facilitate fully integrated, continuous production of biologics, complete with real-time monitoring capabilities, improved operational efficiency, and uniform product quality. As an illustration, Enzene Biosciences Ltd., an Indian contract development and manufacturing organization, unveiled EnzeneX 2.0, the subsequent iteration of its fully connected continuous manufacturing (FCCM) technology for biologics, at CPHI Milan 2024 in October 2024. This proprietary platform facilitates uninterrupted processing, from perfusion through to the ultimate drug substance. Utilizing high-titer clones and refined cell media, it improves productivity, elevates target protein concentrations, and reduces variability between batches. Furthermore, the system integrates process analytical technology (PAT) to enable real-time monitoring and control, thereby guaranteeing consistent quality and operational effectiveness, alongside providing up to a 50% decrease in production costs per gram. Such platforms deliver scalable, economical biologics manufacturing solutions that are adaptable to various modalities and media formulations.
Who Are The Primary Competitors In The Global Continuous Bio-Manufacturing Skid Market?
Major companies operating in the continuous bio-manufacturing skid market are Thermo Fisher Scientific Inc., Danaher Corporation, Merck KGaA, Garrett Industrial Systems Ltd., Sartorius AG, Getinge AB, ZETA GmbH, Pall Corporation, Repligen Corporation, ABEC Inc., Enzene Biosciences Limited, Pierre Guerin Technologies, Bioengineering AG, KeyPlants GmbH, G&G Technologies Pvt. Ltd., Scigenics Pvt. Ltd, Exentec B.V., PAK BioSolutions Inc., Stobbe Pharma GmbH, CPi Biotech Inc.
Access The Complete Report For Deeper Market Insights:
Which Global Regions Are Shaping The Competitive Landscape Of The Continuous Bio-Manufacturing Skid Market?
North America was the largest region in the continuous bio-manufacturing skid market in 2025. The regions covered in the continuous bio-manufacturing skid market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request Your Customized Continuous Bio-Manufacturing Skid Market Research Report for Competitive Advantage:
https://www.thebusinessresearchcompany.com/customise?id=28999&type=smp
Browse Through More Reports Similar to the Global Continuous Bio-Manufacturing Skid Market 2026, By The Business Research Company
Digital Biomanufacturing Market Report 2026
https://www.thebusinessresearchcompany.com/report/digital-biomanufacturing-global-market-report
Biopharmaceuticals Contract Manufacturing Market Report 2026
Bioengineering Technology Market Report 2026
https://www.thebusinessresearchcompany.com/report/bioengineering-technology-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model